Vedaprofen — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	0.5 mg/kg	q24h	Duration: Up to 28 days for osteoarthritis; 3-5 days for post-operative pain Notes: Administer with food to reduce gastrointestinal upset. Use the lowest effective dose for the shortest duration.
Horse	PO	2 mg/kg	q24h	Duration: Up to 14 days for musculoskeletal disorders; 3-5 days for post-operative pain Notes: Administer as a paste or oral suspension. Monitor for gastrointestinal signs.

Clinical Indications & Species Uses

General Indications

Anti-inflammatory, analgesic, and antipyretic for use in dogs and horses

Dog (Canine)

Treatment of inflammation and pain associated with musculoskeletal disorders, such as osteoarthritis
Post-operative pain and inflammation

Horse (Equine)

Treatment of inflammation and pain associated with musculoskeletal disorders, such as lameness
Post-operative pain and inflammation

Pharmacology & Mechanism of Action

Drug Class: Non-Steroidal Anti-Inflammatory Drug (NSAID) | Pharmacological Group: Propionic acid derivative

Mechanism of Action: Vedaprofen is a non-selective cyclooxygenase (COX) inhibitor, blocking both COX-1 and COX-2 enzymes, thereby reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This leads to anti-inflammatory, analgesic, and antipyretic effects. It also inhibits neutrophil migration and reduces the production of reactive oxygen species, contributing to its anti-inflammatory action.

Pharmacodynamics: Vedaprofen produces dose-dependent inhibition of prostaglandin synthesis. It has a rapid onset of action, with significant reduction in inflammation and pain within hours. Its anti-inflammatory potency is comparable to other propionic acid derivatives. It also has a mild anti-pyretic effect. The drug's effect on COX-1 may lead to gastrointestinal and renal side effects, especially with prolonged use.

⚡ Pharmacokinetics Summary

Absorption: Vedaprofen is well absorbed after oral administration in dogs and horses. Peak plasma concentrations are reached within 1-2 hours in dogs and 1-3 hours in horses. Food may delay absorption but not the extent.

Distribution: Vedaprofen is highly protein-bound (>99%) in plasma. It distributes into synovial fluid, achieving concentrations that parallel plasma levels. It has a small volume of distribution, indicating limited tissue penetration.

Metabolism: Vedaprofen is extensively metabolized in the liver, primarily via oxidation and conjugation. The main metabolite is the 4-hydroxy derivative, which is pharmacologically inactive.

Excretion: Excretion is primarily via the bile into feces, with a smaller amount excreted in urine. In dogs, about 70% is eliminated in feces and 30% in urine. In horses, similar routes are observed.

Half-Life: Dog: 4-6 hours; Horse: 2-4 hours.

Bioavailability: Oral bioavailability is approximately 100% in dogs and horses.

Protein Binding: >99% in dogs and horses.

Available Formulations & Strengths

Oral Tablet 20 mg, 50 mg, 100 mg (PO)

Oral Paste 100 mg/g (PO)

Oral Suspension 50 mg/mL (PO)

Contraindications & Clinical Warnings

Contraindications:

Known hypersensitivity to vedaprofen or other NSAIDs
Active gastrointestinal ulceration or bleeding
Renal or hepatic impairment
Bleeding disorders (e.g., thrombocytopenia, coagulopathies)
Concurrent use of other NSAIDs or corticosteroids
Pregnancy, especially in the last trimester
Lactating animals (safety not established)

Warnings & Clinical Precautions:

Use with caution in animals with pre-existing renal, hepatic, or cardiac disease
Monitor for gastrointestinal signs (vomiting, diarrhea, melena) during therapy
Avoid use in dehydrated, hypovolemic, or hypotensive animals
Use with caution in young or geriatric animals
Do not exceed recommended dose or duration
In horses, monitor for signs of colic or laminitis
Not for use in cats or other small animals due to narrow safety margin

Adverse Effects & Reactions

Common:

Gastrointestinal upset (vomiting, diarrhea, decreased appetite)
Elevated liver enzymes
Renal function changes (increased BUN/creatinine)

Serious / Severe:

Gastrointestinal ulceration and perforation
Acute renal failure
Hepatotoxicity
Bone marrow suppression (rare)

Rare:

Hypersensitivity reactions (skin rash, anaphylaxis)
Neurological signs (ataxia, seizures)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Other NSAIDs (e.g., meloxicam, carprofen)	Increased risk of gastrointestinal ulceration and renal toxicity	High
Corticosteroids (e.g., prednisone, dexamethasone)	Increased risk of gastrointestinal ulceration and renal toxicity	High
Anticoagulants (e.g., warfarin, heparin)	Increased risk of bleeding due to platelet inhibition	High
Diuretics (e.g., furosemide)	Reduced diuretic efficacy and increased risk of renal toxicity	Moderate
ACE inhibitors (e.g., enalapril)	Reduced antihypertensive effect and increased risk of renal impairment	Moderate
Aminoglycoside antibiotics	Increased risk of nephrotoxicity	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Vomiting
Diarrhea
Gastrointestinal ulceration
Renal failure
Depression
Ataxia
Seizures (in severe cases)

Emergency Treatment Protocol: Induce emesis if within 2 hours of ingestion. Administer activated charcoal to reduce absorption. Provide symptomatic and supportive care: intravenous fluids, gastroprotective agents (e.g., omeprazole, misoprostol), and monitoring of renal and hepatic function. In severe cases, consider hemodialysis or peritoneal dialysis.

Food Animal Withdrawal Times

Vedaprofen is not approved for use in food-producing animals. Withdrawal times are not established. Do not use in animals intended for human consumption.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25°C, excursions permitted to 15-30°C).

Handling & Special Conditions: Protect from moisture. Keep container tightly closed.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use in the US. Approved in some countries (e.g., European Union) for use in dogs and horses.

Extra-Label (Off-Label) Use: In the US, vedaprofen is not approved by the FDA for veterinary use. It may be used under the Animal Medicinal Drug Use Clarification Act (AMDUCA) for non-food animals only. Extra-label use in food animals is prohibited.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Vedaprofen is a propionic acid NSAID used primarily in dogs and horses for the management of pain and inflammation associated with musculoskeletal disorders. It is not approved in the US but is available in other regions. Due to its non-selective COX inhibition, it carries a risk of gastrointestinal and renal adverse effects. It should be used with caution, especially in animals with pre-existing conditions. The drug has a relatively short half-life, allowing for once-daily dosing. In horses, it is often used for lameness and post-operative pain. Always use the lowest effective dose for the shortest duration. Monitor for adverse effects, especially gastrointestinal signs. Not recommended for use in cats or other small animals due to safety concerns. For food animals, withdrawal times are not established, and use is prohibited.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)